Pirfenidone: In idiopathic pulmonary fibrosis

Drugs

Volumn 71, Issue 13, 2011, Pages 1721-1732

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Idiopathic pulmonary fibrosis; Pirfenidone

Indexed keywords

AMIODARONE; CHLORAMPHENICOL; CIGARETTE SMOKE; CIPROFLOXACIN; CYTOCHROME P450 1A2; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; LIVER ENZYME; OMEPRAZOLE; PAROXETINE; PIRFENIDONE; PROPAFENONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DECREASED APPETITE; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GRAPEFRUIT JUICE; HOT FLUSH; HUMAN; JAPAN; NAUSEA; NONHUMAN; PHOTOSENSITIVITY DISORDER; PNEUMOTHORAX; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; STOMACH DISCOMFORT; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80052613002     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207710-000000000-00000     Document Type: Article

References (38)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 Mar 15; 183 (6): 788-824
2. Hauber H-P, Blaukovitsch M. Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 2010 Jul 1; 9 (3): 158-72
3. European Medicines Agency. Public summary of opinion on orphan designation: pirfenidone for the treatment of idiopathic pulmonary fibrosis (EMA/COMP/198295/2004 Rev. 2) [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/documentlibrary/Orphan-design ation/2009/10/WC500006133.pdf [Accessed 2011 Jun 7]
4. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis [letter]. Lancet 2011 May 21; 377 (9779): 1727-9
5. InPharm. First idiopathic pulmonary fibrosis drug approved [online]. Available from URL: http://www. inpharm.com/news/149931/intermune-idiopathic- pulmonaryfibrosis-esbriet-pirfenidone [Accessed 2011 Jul 12]
6. Mac̈́as-Barragán J, Sandoval-Rodr̈ ́guez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010; 3: 16
7. Jackson RM, Gomez-Marin O. Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials. Transpl Res Risk Manag 2011; 3: 55-63
8. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycininduced murine pulmonary fibrosis. Eur J Pharmacol 2008 Aug 20; 590 (1-3): 400-8
9. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999 Oct; 291 (1): 367-73 (Pubitemid 29451612)
10. European Medicines Agency. Esbriet: CHMP assessment report (EMA/CHMP/115147/2011) [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/documentlibrary/EPAR-Public-assessmentreport/human/002154/ WC500103073.pdf [Accessed 2011 May 1]
11. Gurujeyalakshmi G, Hollinger MA, Giri SN, et al. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999 Feb 1; 276 (2): L311-8 (Pubitemid 29102273)
12. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999 Apr; 289 (1): 211-8 (Pubitemid 29156031)
13. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Labs Clin Med 1995; 125: 779-85
14. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011 Jun 1; 20 (120): 85-97
15. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycininduced pulmonary fibrosis. Eur Respir J 2004 Jul; 24 (1): 57-65 (Pubitemid 39029069)
16. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000 Oct; 24 (5): 477-91 (Pubitemid 30452555)
17. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003 Aug; 16 (4): 207-14 (Pubitemid 36798118)
18. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002 Jun 20; 446 (1-3): 167-76 (Pubitemid 34722571)
19. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level. Eur J Pharmacol 2002 Jun 20; 446 (1-3): 177-85 (Pubitemid 34722572)
20. Koyama S, Kamijyo S, Hashizume M, et al. Pirfenidone attenuates the release of neutrophil (NCA) and monocyte chemotactic activity (MCA) from human lung fibroblasts (FLH-1) in response to tumor necrosis factor (TNF)-alpha [abstract]. Am J Respir Crit Care Med 2010 May 1; 181 Suppl.: A3529
21. Misra H, Rabideau C. Pirfenidone inhibits NADPHdependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Molec Cell Biochem 2000 Jan; 204 (1-2): 119-26 (Pubitemid 30111765)
22. Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro . J Environ Pathol Toxicol Oncol 1999; 18 (3): 169-77
23. Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun 2008 Jul; 372 (1): 19-23 (Pubitemid 351778163)
24. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) downregulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72-6 (Pubitemid 28329068)
25. Shi S, Wu J, Chen H, et al. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007 Oct; 47 (10): 1268-76 (Pubitemid 47459661)
26. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009 Aug; 22 (4): 279-85
27. InterMune. Esbriet(pirfenidone): EU summary of product characteristics [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/ documentlibrary/EPAR-ProductInformation/human/002154/WC500103049.pdf [Accessed 2011 May 11]
28. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999 Apr 1; 159 (4): 1061-9 (Pubitemid 29202536)
29. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002 Dec; 41 (12): 1118-23 (Pubitemid 36150010)
30. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.AmJ Respir Crit CareMed 2005May 1; 171 (9): 1040-7 (Pubitemid 40616955)
31. Noble PW, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779): 1760-9
32. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010 Apr; 35 (4): 821-9
33. Costabel U, Albera C, Bradford W, et al. Pirfenidone doseresponse in patients with idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of outcomes in CAPACITY 2 [abstract no. 388]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18-22; Barcelona
34. Valeyre D, Albera C, Bradford W, et al. The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): analysis of outcomes in the CAPACITY (CAP) trials [abstract no. 391]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18-22; Barcelona
35. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011 Feb; 183 (4): 431-40
36. Albera C, Bradford W, Costabel U, et al. The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): a pooled analysis of outcomes in the CAPACITY (CAP) studies [abstract no. 389]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18-22; Barcelona
37. ClinicalTrials.gov. Efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) (ASCEND): NCT01366209 [online]. Available from URL: http://clinical trials.gov/ct2/show/NCT01366209?term= pirfenidone&rank=4 [Accessed 2011 Jun 16]
38. InterMune. InterMune to provide overview of corporate strategy, update on Esbrietcommercialization plans in the EU and details of phase 3 ASCEND study [online]. Available from URL: http://phx.corporate-ir.net/phoe nix.zhtml?c=100067&p=irol-newsArticle&ID=1567821&highlight= [Accessed 2011 Jun 16]